Seattle Genova offers our customers excellent protein production services that keep the bioactivities of your proteins just as they were in nature. To achieve this, we can offer both nature protein purification services and recombinant protein production services. We have developed very specialized protocols to make sure the produced proteins will maintain their biological activities. And our well-developed bioassays can ensure comprehensive activity validations before we release the proteins.
Immunotherapy has been considered a greatly exciting development in cancer treatment for a long time after years of scientific research and clinical trials. Immunotherapy is a treatment that is formulated to harness the potential of the body's immune system to combat infection or disease, such as cancer, allergy and autoimmune disease. Vaccines, monoclonal antibodies, cytokines are the representative categories of immunotherapy treatments.
The various types of immunotherapy include:
•Monoclonal antibodies and immune checkpoint inhibitors
•Oncolytic virus therapy
Monoclonal antibodies are made in a laboratory to increase the body’s natural antibodies or act as antibodies themselves. Monoclonal antibodies can enable fight cancer in various ways. For instance, they can be utilized to block the activity of abnormal proteins in cancer cells. This is also considered a type of targeted therapy, which is a cancer treatment using medication that targets a cancer’s specific genes, proteins, or the tissue environment that helps the tumor grow and survive.
Immune checkpoints are utilized by the body to generally stop an immune system response and prevent the immune system from attacking healthy cells. Cancer cells can find paths to hide from the immune system by activating these checkpoints.
Examples of immune checkpoint inhibitors include:
There are various types of non-specific immunotherapies that work in several ways.
•Bacillus Calmette-Guerin (BCG)
Oncolytic virus therapy
A genetically modified version of the virus is inserted into the tumor. When the virus arrives in the cancer cells, it gives rise to a copy of itself. As an outcome, the cancer cells broken and die. As the cells die, they discharge proteins that trigger your immune system to target any cancer cells in your body that have the similar proteins as the dead cancer cells. The virus does not arrive healthy cells.
T cells are immune cells that fight against infection. In T-cell therapy, the doctor eliminates T cells from the blood. Chimeric antigen receptor (CAR) T-cell therapy is utilized to treat certain blood cancers. Researchers are still researching this category of therapy and other paths of changing T cells to treat cancer.
A cancer vaccine can also enable your body fight disease. A vaccine uncovers your immune system to a foreign protein called an antigen. This triggers the immune system to identify and destroy that antigen or related substances. There are 2 kinds of cancer vaccines: prevention vaccines and treatment vaccines.
Advantages of immunotherapy
➢Immunotherapies are still less popular than surgery or chemotherapy to treat cancer. But for some kinds of cancer, these therapies are now a significant treatment option.
➢Immunotherapies have the potential to be more extensive and less toxic than other kinds of treatments for cancer because they harness the power of the body itself to attack the tumour rather than initiating chemicals into the body.
Our Working Process
Expert Technical Support
Technical support is given by every scientist that develops the assays.
Quality and User-friendly
Products are extensively assessed and validated before release so researchers need little-to-no time for assay optimization.
With complete control over all quality testing, Seattle Genova can generate proteins to meet industry-leading purity specifications
Each new production lot of protein is assessed for endotoxin using the Limulus Amoebocyte Lysates (LAL) assay. Our basic endotoxin specification is an industry-leading <0.1 EU/ug.
∗Western blotting data
∗Bioactivity validation data
1.Immunotherapy | Memorial Sloan Kettering Cancer Center”. Mskcc.org. Retrieved 2017-07-27.
2. Syn NL, Teng MW, Mok TS, Soo RA (December 2017). “De-novo and acquired resistance to immune checkpoint targeting”. The Lancet. Oncology. 18 (12): e731–e741.
3. Conforti L (February 2012). "The ion channel network in T lymphocytes, a target for immunotherapy". Clinical Immunology. 142 (2): 105–106.
4. Wang, S., Zimmermann, S., Parikh, K., Mansfield, A.S., Adjei, A.A. (2019). Current diagnosis and management of small-cell lung cancer. Mayo Clinic Proceedings, 94(8), 1599–1622.
Thank you for your interest in our BioActive™ Immunotherapy Protein Production Services services. Please complete the form below and we will contact you shortly.
Fields indicated by an * are required.